Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulevostinag (MK-1454) with or without pembrolizumab in advanced/metastatic solid tumors or lymphomas
NCT03010176Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2017
- Primary completion
- Apr 2022
- Modality
- Modified DNA Aptamers, Vaccines & Immunotherapeutics, Spiegelmers
- Countries
- 5
01
Overview
Phase 1, open-label trial of Ulevostinag in solid tumor, lymphoma, head and neck squamous cell carcinoma (HNSCC) and 1 more (6 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicity at 21 days, Adverse Events at 2 years and 1 more. Started Feb 2017; status: completed.
02
Drugs
Ulevostinag
03
Conditions
solid tumorlymphomahead and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03010176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010176.